NCT05026996View on ClinicalTrials.gov

Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

November 23, 2021

Primary Completion Date

October 19, 2022

Study Completion Date

October 19, 2022

Conditions
Hepatic Impairment
Interventions
DRUG

Pelacarsen

Single subcutaneous injection of pelacarsen

Trial Locations (1)

78215

Novartis Investigative Site, San Antonio

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY